Tisagenlecleucel† (4), (5) | B-ALL and high-grade B-cell lymphoma | CD19 |
|
Axicabtagene ciloleucel† (6) | High-grade B-cell lymphoma | CD19 | 58% OS at 18 mo |
Brexucabtagene autoleucel† (7) | Mantle cell lymphoma | CD19 | 83% OS at 1 yr |
Idecabtagene vicleucel† (8) | Multiple myeloma | BCMA | Median PFS of 11.8 mo |
Lisocabtagene maraleucel‡ (9) | High-grade B-cell lymphoma | CD19 | Median OS of 18.8 mo |